Delineating pro-angiogenic myeloid cells in cancer therapy

Benjamin W. Johnson, Bhagelu R. Achyut, Sadanand Fulzele, Ashis K. Mondal, Ravindra Kolhe, Ali S. Arbab

Research output: Contribution to journalReview article

Abstract

Recent evidence suggests that myeloid cells are critical in cancer development and therapy resistance processes. Pharmacological targeting of tumor-associated myeloid cells is an emerging approach among upcoming immune therapies. Surprisingly, myeloid cells are heterogeneous, including a subset of the myeloid cell displaying angiogenic properties in solid tumors. There is an urgent need to delineate angiogenic myeloid cell populations in order to facilitate specific targeting of protumor myeloid cells among heterogeneous pool. This review article is intended to compile all the relevant information in the literature for improved understanding of angiogenic myeloid cells and their role in tumor refractoriness to cancer therapy.

Original languageEnglish (US)
Article number2565
JournalInternational journal of molecular sciences
Volume19
Issue number9
DOIs
StatePublished - Sep 2018

Fingerprint

Myeloid Cells
Tumors
therapy
cancer
cells
Neoplasms
tumors
Therapeutics
Cells
set theory
emerging
Pharmacology
Population

Keywords

  • Angiogenic
  • Antiangiogenic
  • Chemotherapy
  • Immunotherapy
  • MDSC
  • Myeloid
  • Radiotherapy
  • Tumor

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Delineating pro-angiogenic myeloid cells in cancer therapy. / Johnson, Benjamin W.; Achyut, Bhagelu R.; Fulzele, Sadanand; Mondal, Ashis K.; Kolhe, Ravindra; Arbab, Ali S.

In: International journal of molecular sciences, Vol. 19, No. 9, 2565, 09.2018.

Research output: Contribution to journalReview article

@article{4db2148bba0d49d0a82c420fdaf0b64b,
title = "Delineating pro-angiogenic myeloid cells in cancer therapy",
abstract = "Recent evidence suggests that myeloid cells are critical in cancer development and therapy resistance processes. Pharmacological targeting of tumor-associated myeloid cells is an emerging approach among upcoming immune therapies. Surprisingly, myeloid cells are heterogeneous, including a subset of the myeloid cell displaying angiogenic properties in solid tumors. There is an urgent need to delineate angiogenic myeloid cell populations in order to facilitate specific targeting of protumor myeloid cells among heterogeneous pool. This review article is intended to compile all the relevant information in the literature for improved understanding of angiogenic myeloid cells and their role in tumor refractoriness to cancer therapy.",
keywords = "Angiogenic, Antiangiogenic, Chemotherapy, Immunotherapy, MDSC, Myeloid, Radiotherapy, Tumor",
author = "Johnson, {Benjamin W.} and Achyut, {Bhagelu R.} and Sadanand Fulzele and Mondal, {Ashis K.} and Ravindra Kolhe and Arbab, {Ali S.}",
year = "2018",
month = "9",
doi = "10.3390/ijms19092565",
language = "English (US)",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

TY - JOUR

T1 - Delineating pro-angiogenic myeloid cells in cancer therapy

AU - Johnson, Benjamin W.

AU - Achyut, Bhagelu R.

AU - Fulzele, Sadanand

AU - Mondal, Ashis K.

AU - Kolhe, Ravindra

AU - Arbab, Ali S.

PY - 2018/9

Y1 - 2018/9

N2 - Recent evidence suggests that myeloid cells are critical in cancer development and therapy resistance processes. Pharmacological targeting of tumor-associated myeloid cells is an emerging approach among upcoming immune therapies. Surprisingly, myeloid cells are heterogeneous, including a subset of the myeloid cell displaying angiogenic properties in solid tumors. There is an urgent need to delineate angiogenic myeloid cell populations in order to facilitate specific targeting of protumor myeloid cells among heterogeneous pool. This review article is intended to compile all the relevant information in the literature for improved understanding of angiogenic myeloid cells and their role in tumor refractoriness to cancer therapy.

AB - Recent evidence suggests that myeloid cells are critical in cancer development and therapy resistance processes. Pharmacological targeting of tumor-associated myeloid cells is an emerging approach among upcoming immune therapies. Surprisingly, myeloid cells are heterogeneous, including a subset of the myeloid cell displaying angiogenic properties in solid tumors. There is an urgent need to delineate angiogenic myeloid cell populations in order to facilitate specific targeting of protumor myeloid cells among heterogeneous pool. This review article is intended to compile all the relevant information in the literature for improved understanding of angiogenic myeloid cells and their role in tumor refractoriness to cancer therapy.

KW - Angiogenic

KW - Antiangiogenic

KW - Chemotherapy

KW - Immunotherapy

KW - MDSC

KW - Myeloid

KW - Radiotherapy

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=85052615392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052615392&partnerID=8YFLogxK

U2 - 10.3390/ijms19092565

DO - 10.3390/ijms19092565

M3 - Review article

C2 - 30158456

AN - SCOPUS:85052615392

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 9

M1 - 2565

ER -